Cargando…
Yescarta: A New Era for Non-Hodgkin Lymphoma Patients
The use of conventional therapeutic approaches in patients with lymphoma demonstrates significant drug resistance leading to poor prognosis with reduced median survival period. T-cell immunotherapy has diverted huge attention of the researchers in recent times to engage in the stated research studie...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744214/ https://www.ncbi.nlm.nih.gov/pubmed/33354449 http://dx.doi.org/10.7759/cureus.11504 |